MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: sitagliptin phosphate (+) metformin hydrochloride
Drug: metformin
First Posted Date
2007-06-05
Last Posted Date
2017-06-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1246
Registration Number
NCT00482729

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Esmirtazapine
Drug: Placebo
First Posted Date
2007-06-05
Last Posted Date
2018-10-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
526
Registration Number
NCT00482612

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
First Posted Date
2007-06-05
Last Posted Date
2015-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
45
Registration Number
NCT00482235

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Phase 2
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2007-06-05
Last Posted Date
2015-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
11
Registration Number
NCT00482417

To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Phase 2
Completed
Conditions
Obesity
First Posted Date
2007-06-05
Last Posted Date
2015-04-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
173
Registration Number
NCT00482196

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Phase 2
Completed
Conditions
Type II Diabetes Mellitus
Interventions
Drug: Placebo to sitagliptin
Drug: Sitagliptin
Drug: Rescue
Drug: Metformin
First Posted Date
2007-06-04
Last Posted Date
2017-04-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
555
Registration Number
NCT00481663

A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

Phase 3
Completed
Conditions
Intra-abdominal Infection
First Posted Date
2007-06-04
Last Posted Date
2017-02-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT00481702

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Phase 2
Completed
Conditions
Diabetes Mellitus, Type II
First Posted Date
2007-06-04
Last Posted Date
2017-03-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
743
Registration Number
NCT00482079

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Phase 3
Completed
Conditions
Primary Hypercholesterolemia
Mixed Dyslipidemia
Interventions
Drug: niacin (+) laropiprant
First Posted Date
2007-05-28
Last Posted Date
2015-03-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1216
Registration Number
NCT00479388

Dose-Range Finding Study for MK0893 (0893-008)

Phase 2
Terminated
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: MK0893
Drug: Metformin
Drug: Placebo to MK0893
Drug: Placebo to Metformin
First Posted Date
2007-05-28
Last Posted Date
2015-09-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
342
Registration Number
NCT00479466
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy